Comparative Pharmacology
Head-to-head clinical analysis: AMERSCAN MDP KIT versus AMMONIA N 13.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMERSCAN MDP KIT versus AMMONIA N 13.
AMERSCAN MDP KIT vs AMMONIA N 13
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m medronate is a bone-seeking radiopharmaceutical that localizes in bone by chemisorption to hydroxyapatite crystals, particularly in areas of increased osteoblastic activity.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
Intravenous administration of 10-20 mCi (370-740 MBq) for adult bone imaging. Administer 2-4 hours prior to imaging.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
None Documented
None Documented
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) for the diphosphonate component; reflects clearance from bone and renal elimination.
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Renal: approximately 50-60% unchanged within 2-3 hours post-injection; biliary/fecal: negligible (<5%). The remainder is retained in bone (up to 40%) with slow release.
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical